La Roche-Posay's newest formula helps treat, prevent skin redness
NEW YORK — La Roche-Posay is launching in March its new Rosaliac AR Intense Localized Redness Intensive Care, which reduces visible redness and irritation, and is suitable for rosacea-prone skin.
The formulation not only reduces visible redness but also can help prevent the progression of redness. Most redness-prone skins have a compromised skin barrier and can be highly reactive to environmental factors and traditional skin treatments. Rosaliac AR Intense Localized Redness Intensive Care is formulated free of potentially irritating ingredients/preservatives and sealed airtight in a 100% hermetic package. Twenty-four hour hydration helps rebuild a compromised barrier; instant light-diffusing formula neutralizes redness on contact.
The formulation is free of preservatives, parabens, fragrance, alcohol, colorant and lanolin. It is tested on erythematotelangiectatic (with redness and the appearance of small blood vessels) skin and subjects with atopic (hypersensitive) skin. With a patented high-protection, ultra-hermetic packaging — developed by La Roche-Posay laboratories with a pharmaceutical pump specialist — the product boasts zero contamination, oxidation, dry residue or waste, the company stated.
Rosaliac AR Intense Localized Redness Intensive Care serum has a suggested retail price of $39.95 and can be purchased at select physicians’ offices, select CVS/pharmacy, Ulta, Walgreens and Duane Reade locations beginning in March 2012.